Synapse - Find an Expert

5250 Results

Intraventricular approaches

Book Section

Uribe-Cardenas, R.; Souweidane, M. M.
In Evans, J. J.; Kenning, T. J.; Farrell, C.; Kshettry, V. R. (Eds.) Endoscopic and Keyhole Cranial Base Surgery (2019)

Fulltext@MSK | Save

Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: A report from the Children’s Oncology Group

Journal Article

Kopp, L. M.; Womer, R. B.; Schwartz, C. L.; Ebb, D. H.; Franco, V. I.; Hall, D.; Barkauskas, D. A.; Krailo, M. D.; Grier, H. E.; Meyers, P. A.; more...
Cardio-Oncology (2019)

Fulltext@MSK | Save

Inotuzumab ozogamicin is an effective salvage therapy in relapsed/refractory B-cell acute lymphoblastic leukemia with high-risk molecular features, including TP53 loss

Meeting Abstract

Yang, X.; King, A. C.; Kabel, C. C.; Forlenza, C. J.; Park, J. H.; Geyer, M. B.
Blood (2019)

Fulltext@MSK | Save

Long-term outcomes of subjects with Epstein-Barr virus-driven post-transplant lymphoproliferative disorder (EBV+PTLD) following solid organ (SOT) or allogeneic hematopoietic cell transplants (HCT) treated with tabelecleucel on an expanded access program

Meeting Abstract

Prockop, S.; Reshef, R.; Tsai, D. E.; Bunin, N.; Abu-Arja, R.; Mahadeo, K. M.; Weng, W. K.; Van Besien, K.; Loeb, D.; Nasta, S. D.; more...
Blood (2019)

Fulltext@MSK | Save

A multicenter, open label, phase 3 study of tabelecleucel for solid organ transplant subjects with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+PTLD) after failure of rituximab or rituximab and chemotherapy

Meeting Abstract

Prockop, S.; Hiremath, M.; Ye, W.; Gamelin, L.; Navarro, W.; Mahadeo, K. M.
Blood (2019)

Fulltext@MSK | Save

PD-L1 checkpoint blockade augments anti-tumor immune response of GD2 or HER2-BsAb ex vivo armed T-cells (EVAT) therapy in osteosarcoma

Meeting Abstract

Park, J. A.; Guo, H. F.; Xu, H.; Cheung, N. K. V.
Blood (2019)

Fulltext@MSK | Save

Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory children and young adults with acute lymphoblastic leukemia (ALL): Real world experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and cellular therapy (CT) registry

Meeting Abstract

Grupp, S.; Hu, Z. H.; Zhang, Y.; Keating, A.; Pulsipher, M. A.; Philips, C.; Margossian, S. P.; Rosenthal, J.; Salzberg, D.; Schiff, D. E.; more...
Blood (2019)

Fulltext@MSK | Save

Allogeneic CD34-selected HSCT following CAR T-cells is associated with low TRM and favorable OS in pediatric/young adult patients with relapsed/refractory B-ALL